Hiroyuki KUSUHARA   SITE

  • Cancer Chemother Pharmacol. 2021;88:543-553. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure. Tsuboya A, Kubota Y, Ishida H, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Sasaki Y, Matsumoto N, Kondo Y, Tomoda Y, Kusuhara H, Fujita KI. PubMed
  • Stem Cell Reports. 2021;16:295-308. Generation of human-induced pluripotent stem cell-derived functional enterocyte-like cells for pharmacokinetic studies. Yoshida S, Honjo T, Iino K, Ishibe R, Leo S, Shimada T, Watanabe T, Ishikawa M, Maeda K, Kusuhara H, Shiraki N, Kume S. PubMed
  • Drug Metab Pharmacokinet. 2021;37:100358. Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development. Mochizuki T, Mizuno T, Maeda K, Kusuhara H. PubMed
  • Stem Cell Reports. 2021;16:309-323. Modeling human bile acid transport and synthesis in stem cell-derived hepatocytes with a patient-specific mutation. Hayashi H, Osaka S, Sakabe K, Fukami A, Kishimoto E, Aihara E, Sabu Y, Mizutani A, Kusuhara H, Naritaka N, Zhang W, Huppert SS, Sakabe M, Nakamura T, Hu YC, Mayhew C, Setchell K, Takebe T, Asai A. PubMed
  • Hepatol Commun. 2020;5:52-62.  Assessment of Adenosine Triphosphatase Phospholipid Transporting 8B1 (ATP8B1) function in patients with cholestasis with ATP8B1 deficiency by using peripheral blood monocyte-derived macrophages. Mizutani A, Sabu Y, Naoi S, Ito S, Nakano S, Minowa K, Mizuochi T, Ito K, Abukawa D, Kaji S, Sasaki M, Muroya K, Azuma Y, Watanabe S, Oya Y, Inomata Y, Fukuda A, Kasahara M, Inui A, Takikawa H, Kusuhara H, Bessho K, Suzuki M, Togawa T, Hayashi H. PubMed
  • Drug Metab Dispos. 2021;49:152-158.  Impact of direction of transport on the evaluation of inhibition potencies of multidrug and toxin extrusion protein 1 (MATE1) inhibitors. Saito A, Ishiguro N, Takatani M, Bister B, Kusuhara H. PubMed
  • Drug Metab Dispos. 2021;49:3-11. Functional investigation of Solute Carrier Family 35, member F2, in three cellular models of the primate Blood-Brain Barrier. Mochizuki T, Mizuno T, Kurosawa T, Yamaguchi T, Higuchi K, Tega Y, Nozaki Y, Kawabata K, Deguchi Y, Kusuhara H. PubMed
  • J Pharm Sci. 2020;In press. Evaluation of hepatic uptake of OATP1B substrates by short term-cultured plated human hepatocytes: Comparison with isolated suspended hepatocytes. Yoshikado T, Lee W, Toshimoto K, Morita K, Kiriake A, Chu X, Lee N, Kimoto E, Varma MVS, Kikuchi R, Scialis RJ, Shen H, Ishiguro N, Lotz R, Li AP, Maeda K, Kusuhara H, Sugiyama Y. PubMed
  • Drug Metab Dispos. 2020;In press. Characterization of the human intestinal drug transport with Ussing chamber system incorporating freshly-isolated human jejunum. Michiba K, Maeda K, Kurimori K, Enomoto T, Shimomura O, Takeuchi T, Nishiyama H, Oda T, Kusuhara H. PubMed
  • AAPS J. 2020;22:133. Cell-to-Medium concentration ratio overshoot in the uptake of statins by human hepatocytes in suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs. Lee W, Koyama S, Morita K, Kiriake A, Kikuchi R, Chu X, Lee N, Scialis RJ, Shen H, Kimoto E, Tremaine L, Ishiguro N, Lotz R, Maeda K, Kusuhara H, Sugiyama Y. PubMed
  • Drug Metab Dispos. 2020;48:1183-1190. Impact of P-Glycoprotein-mediated active efflux on drug distribution into lumbar cerebrospinal fluid in nonhuman primates. Nagaya Y, Katayama K, Kusuhara H, Nozaki Y. PubMed
  • Differentiation. 2020;114:36-48. Analysis of hiPSCs differentiation toward hepatocyte-like cells upon extended exposition to oncostatin. Danoy M, Tauran Y, Poulain S, Arakawa H, Mori D, Araya K, Kato S, Kido T, Kusuhara H, Kato Y, Miyajima A, Plessy C, Sakai Y, Leclerc E. PubMed
  • Mol Pharm. 2020;17:1884-1898. Practical synthesis of [18F]Pitavastatin and evaluation of hepatobiliary transport activity in rats by Positron Emission Tomography. Nakaoka T, Uetake Y, Kaneko KI, Niwa T, Ochiai H, Irie S, Suezaki Y, Otsuka N, Hayashinaka E, Wada Y, Cui Y, Maeda K, Kusuhara H, Sugiyama Y, Hosoya T, Watanabe Y. PubMed
  • Mol Pharm. 2020;17:722-723. Relative Activity Factor (RAF)-based scaling of uptake clearance mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in human hepatocytes. Izumi S, Nozaki Y, Kusuhara H, Hotta K, Mochizuki T, Komori T, Maeda K, Sugiyama Y. PubMed
  • Clin Pharmacol Ther. 2020;107:96-101. Expanding precompetitive multisector collaborations to advance drug development and pharmacogenomics. Yee SW, Do TP, Huang SM, Krauss RM, Kusuhara H, Sugiyama Y, Unadkat JD, Giacomini KM. PubMed
  • Sci Rep. 2019;9:17075. Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis. Nakano S, Osaka S, Sabu Y, Minowa K, Hirai S, Kondou H, Kimura T, Azuma Y, Watanabe S, Inui A, Bessho K, Nakamura H, Kusano H, Nakazawa A, Tanikawa K, Kage M, Shimizu T, Kusuhara H, Zen Y, Suzuki M, Hayashi H. PubMed
  • Biol Pharm Bull. 2019;42:2069-2075. Development of a Novel Platform of Proteome Profiling Based on an Easy-to-Handle and Informative 2D-DIGE System. Kinoshita S1,2,3, Mizuno T1, Hori M2, Kohno M4,5, Kusuhara H1. PubMed
  • Clin Pharmacol Ther. 2019;107:1004-1013. Dose-dependent inhibition of OATP1B by rifampicin in healthy volunteers: Comprehensive evaluation of candidate biomarkers and OATP1B probe drugs. Mori D, Kimoto E, Rago B, Kondo Y, King-Ahmad A, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, David Rodrigues A, Muto C, Furihata K, Sugiyama Y, Kusuhara H. PubMed
  • Drug Metab Pharmacokinet. 2019;34:387-395. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. Lee N, Maeda K, Fukizawa S, Ieiri I, Tomaru A, Akao H, Takeda K, Iwadare M, Niwa O, Masauji T, Yamane N, Kajinami K, Kusuhara H, Sugiyama Y. PubMed
  • Drug Metab Pharmacokinet. 2019;34:293-299. Quantitative investigation of hepatobiliary transport of [11C]telmisartan in humans by PET imaging. Maeda K, Ohnishi A, Sasaki M, Ikari Y, Aita K, Watanabe Y, Kusuhara H, Sugiyama Y, Senda M. PubMed
  • Drug Metab Dispos. 2019;47:1270-1280.  Elucidation of N 1-methyladenosine as a potential surrogate biomarker for drug interaction studies involving renal Organic Cation Transporters. Miyake T, Mizuno T, Takehara I, Mochizuki T, Kimura M, Matsuki S, Irie S, Watanabe N, Kato Y, Ieiri I, Maeda K, Ando O, Kusuhara H. PubMed
  • J Pharm Sci. 2019;108:3898-3902. Proposal of a parameter for OATP1B1 inhibition screening at the early drug discovery stage. Murata H, Ito S, Kusuhara H, Nomura Y, Taniguchi T. PubMed
  • CPT Pharmacometrics Syst Pharmacol. 2019;8:845-857. Expanded Physiologically-Based Pharmacokinetic model of Rifampicin for predicting interactions with drugs and an endogenous biomarker via complex mechanisms including Organic Anion Transporting Polypeptide 1B induction. Asaumi R, Menzel K, Lee W, Nunoya KI, Imawaka H, Kusuhara H, Sugiyama Y. PubMed
  • Drug Metab Pharmacokinet. 2019;34:317-324. Evaluation of transporter-mediated hepatobiliary transport of newly developed 18F-labeled pitavastatin derivative, PTV-F1, in rats by PET imaging. Kimura H, Yagi Y, Mikamo M, Maeda K, Kagawa S, Arimitsu K, Higashi T, Nishii R, Ono M, Nakamoto Y, Togashi K, Kusuhara H, Saji H. PubMed
  • Drug Metab Pharmacokinet. 2019;34:233-238. Estimation of changes in serum creatinine and creatinine clearance caused by renal transporter inhibition in healthy subjects. Nakada T, Kudo T, Kume T, Kusuhara H, Ito K. PubMed
  • J Pharm Sci. 2019;108:2756-2764. Effect of Rifampicin on the plasma concentrations of Bile Acid-O-Sulfates in monkeys and human liver-transplanted chimeric mice with or without bile flow diversion. Takehara I, Watanabe N, Mori D, Ando O, Kusuhara H. PubMed
  • Drug Metab Pharmacokinet. 2019;34:87-94. Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney. Kito T, Ito S, Mizuno T, Maeda K, Kusuhara H. PubMed
  • Drug Metab Pharmacokinet. 2018;pii: S1347-4367(18)30077-6. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Mori D, Kashihara Y, Yoshikado T, Kimura M, Hirota T, Matsuki S, Maeda K, Irie S, Ieiri I, Sugiyama Y, Kusuhara H. PubMed
  • Clin Pharmacol Ther. 2018;104:836-864. Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: Perspectives from the International Transporter Consortium. Chu X, Liao M, Shen H, Yoshida K, Zur AA, Arya V, Galetin A, Giacomini KM, Hanna I, Kusuhara H, Lai Y, Rodrigues D, Sugiyama Y, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. PubMed
  • CPT Pharmacometrics Syst Pharmacol. 2018;7:739-747. PBPK modeling of Coproporphyrin I as an endogenous biomarker for drug interactions involving inhibition of hepatic OATP1B1 and OATP1B3. Yoshikado T, Toshimoto K, Maeda K, Kusuhara H, Kimoto E, Rodrigues AD, Chiba K, Sugiyama Y. PubMed
  • Drug Metab Dispos. 2018;46:1767-1775. Evaluation of Organic Anion Transporter 1A2-knock-in mice as a model of human blood-brain barrier. Sano Y, Mizuno T, Mochizuki T, Uchida Y, Umetsu M, Terasaki T, Kusuhara H. PubMed
  • Drug Metab Dispos. 2018;46:1805-1816. Accurate estimation of in vivo inhibition constants of inhibitors and fraction metabolized of substrates with physiologically based pharmacokinetic drug-drug interaction models incorporating parent drugs and metabolites of substrates with Cluster Newton method. Yoshida K, Maeda K, Konagaya A, Kusuhara H. PubMed
  • Pharm Res. 2018;35:138. Comparative study of the dose-dependence of OATP1B inhibition by rifampicin using probe drugs and endogenous substrates in healthy volunteers. Takehara I, Yoshikado T, Ishigame K, Mori D, Furihata KI, Watanabe N, Ando O, Maeda K, Sugiyama Y, Kusuhara H. PubMed
  • Mol Pharm. 2018;15:2277-2288. Relative Activity Factor (RAF)-based scaling of uptake clearance mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in human hepatocytes. Izumi S, Nozaki Y, Kusuhara H, Hotta K, Mochizuki T, Komori T, Maeda K, Sugiyama Y. PubMed
  • Drug Metab Dispos. 2018;46:719-728. A clinical quantitative evaluation of hepatobiliary transport of [11C]Dehydropravastatin in humans Using Positron Emission Tomography. Kaneko K, Tanaka M, Ishii A, Katayama Y, Nakaoka T, Irie S, Kawahata H, Yamanaga T, Wada Y, Miyake T, Toshimoto K, Maeda K, Cui Y, Enomoto M, Kawamura E, Kawada N, Kawabe J, Shiomi S, Kusuhara H, Sugiyama Y, Watanabe Y. PubMed
  • J Hum Genet. 2018;63:569-577. Clinical phenotype and molecular analysis of a homozygous ABCB11 mutation responsible for progressive infantile cholestasis. Imagawa K, Hayashi H, Sabu Y, Tanikawa K, Fujishiro J, Kajikawa D, Wada H, Kudo T, Kage M, Kusuhara H, Sumazaki R. PubMed
  • Drug Metab Pharmacokinet. 2018;33:103-110. Quantitative analysis of elevation of serum creatinine via renal transporter inhibition by trimethoprim in healthy subjects using physiologically-based pharmacokinetic model. Nakada T, Kudo T, Kume T, Kusuhara H, Ito K. PubMed
  • Drug Metab Dispos. 2018;46:652-657. Organic Anion Transporting Polypeptide 1a4 is responsible for the hepatic uptake of cardiac glycosides in mice. Takano J, Maeda K, Kusuhara H, Sugiyama Y. PubMed
  • Clin Pharmacol Ther. 2018;103:434-448. Endogenous probes for drug transporters: balancing vision with reality. Rodrigues AD, Taskar KS, Kusuhara H, Sugiyama Y. PubMed
  • J Pharm Sci. 2017;106:2542-2550. Involvement of Organic Cation Transporters in the kinetics of Trimethylamine N-oxide. Miyake T, Mizuno T, Mochizuki T, Kimura M, Matsuki S, Irie S, Ieiri I, Maeda K, Kusuhara H. PubMed
  • J Pharm Sci. 2017;106:2524-2534. Different involvement of OAT in renal disposition of oral anticoagulants Rivaroxaban, Dabigatran, and Apixaban. Tsuruya Y, Nakanishi T, Komori H, Wang X, Ishiguro N, Kito T, Ikukawa K, Kishimoto W, Ito S, Schaefer O, Ebner T, Yamamura N, Kusuhara H, Tamai I. PubMed
  • J Pharm Sci. 2017;106:2566-2575. Investigation of the importance of Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4) in the active efflux of anionic drugs across the Blood-Brain Barrier. Kanamitsu K, Kusuhara H, Schuetz JD, Takeuchi K, Sugiyama Y. PubMed
  • J Pharm Sci. 2017;106:2576-2582. Involvement of proton-coupled organic cation antiporter in Varenicline transport at blood-brain barrier of rats and in human brain capillary endothelial cells. Kurosawa T, Higuchi K, Okura T, Kobayashi K, Kusuhara H, Deguchi Y. PubMed
  • J Pharm Sci. 2017;106:2688-2694. Small-dosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1 and ABCG2), and interaction (Atorvastatin and grapefruit juice) profiles of 5 probes for OATP2B1 and BCRP. Kashihara Y, Ieiri I, Yoshikado T, Maeda K, Fukae M, Kimura M, Hirota T, Matsuki S, Irie S, Izumi N, Kusuhara H, Sugiyama Y. PubMed
  • J Pharm Sci. 2017;106:2678-2687. Comparison of the predictability of human hepatic clearance for Organic Anion Transporting Polypeptide substrate drugs between different in vitro-in vivo extrapolation approaches. Izumi S, Nozaki Y, Komori T, Takenaka O, Maeda K, Kusuhara H, Sugiyama Y. PubMed
  • J Hepatol. 2017;66:685-692. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park SY, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T. PubMed
  • Drug Metab Dispos. 2016;44:1925-1933. Investigation of endogenous compounds applicable to drug-drug interaction studies involving the renal organic anion transporters, OAT1 and OAT3, in humans. Tsuruya Y, Kato K, Sano Y, Imamura Y, Maeda K, Kumagai Y, Sugiyama Y, Kusuhara H. PubMed
  • Drug Metab Dispos. 2016;44:1381-9. Impact of experimental conditions on the evaluation of interactions between Multidrug and Toxin Extrusion Proteins and candidate drugs. Lechner C, Ishiguro N, Fukuhara A, Shimizu H, Ohtsu N, Takatani M, Nishiyama K, Washio I, Yamamura N, Kusuhara H. PubMed
  • Clin Pharmacol Ther. 2016 Nov;100:513-523. Quantitative analyses of hepatic OATP-mediated interactions between statins and inhibitors using PBPK modeling with a parameter optimization method. Yoshikado T, Yoshida K, Kotani N, Nakada T, Asaumi R, Toshimoto K, Maeda K, Kusuhara H, Sugiyama Y. PubMed
  • Drug Metab Pharmacokinet. 2016;31:57-66. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats. Nagaya Y, Nozaki Y, Takenaka O, Watari R, Kusano K, Yoshimura T, Kusuhara H. PubMed
  • Mol Pharm. 2016;13:438-48. Investigation of fluorescein derivatives as substrates of Organic Anion Transporting Polypeptide (OATP)1B1 to develop sensitive fluorescence-based OATP1B1 inhibition assays. Izumi S, Nozaki Y, Komori T, Takenaka O, Maeda K, Kusuhara H, Sugiyama Y. PubMed
  • Mol Pharmacol. 2015;88:1085-92. Impaired hepatic uptake by Organic Anion-Transporting Polypeptides is associated with hyperbilirubinemia and hypercholanemia in Atp11c mutant mice. Matsuzaka Y, Hayashi H, Kusuhara H. PubMed
  • Mol Pharm. 2015;12:3175-83. Effect of knockout of Mdr1a and Mdr1b ABCB1 genes on the systemic exposure of a doxorubicin-conjugated block copolymer in mice. Sakai-Kato K, Nanjo K, Kusuhara H, Nishiyama N, Kataoka K, Kawanishi T, Okuda H, Goda Y. PubMed
  • Drug Metab Dispos. 2015;43:1008-18. Solute carrier family of the Organic Anion-Transporting Polypeptides 1A2- Madin-Darby Canine Kidney II: a promising in vitro system to understand the role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier drug penetration. Liu H, Yu N, Lu S, Ito S, Zhang X, Prasad B, He E, Lu X, Li Y, Wang F, Xu H, An G, Unadkat JD, Kusuhara H, Sugiyama Y, Sahi J. PubMed
  • Pharm Res. 2015;32:2192-204. Involvement of organic cation transporters in the clearance and milk secretion of thiamine in mice. Kato K, Moriyama C, Ito N, Zhang X, Hachiuma K, Hagima N, Iwata K, Yamaguchi J, Maeda K, Ito K, Suzuki H, Sugiyama Y, Kusuhara H. PubMed
  • Drug Metab Dispos. 2015;43:235-47. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Izumi S, Nozaki Y, Maeda K, Komori T, Takenaka O1, Kusuhara H, Sugiyama Y. PubMed
  • Eur J Clin Pharmacol. 2014;70:1087-95. Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers. Akamine Y, Miura M, Komori H, Saito S, Kusuhara H, Tamai I, Ieiri I, Uno T, Yasui-Furukori N. PubMed
  • Drug Metab Pharmacokinet. 2014;29:419-26. Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates. Nagaya Y, Nozaki Y, Kobayashi K, Takenaka O, Nakatani Y, Kusano K, Yoshimura T, Kusuhara H. PubMed
  • Drug Metab Dispos. 2014;42:983-9. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters. Kodaira H, Kusuhara H, Fuse E, Ushiki J, Sugiyama Y. PubMed
  • J Pediatr. 2014;164:1219-1227. Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2. Naoi S, Hayashi H, Inoue T, Tanikawa K, Igarashi K, Nagasaka H, Kage M, Takikawa H, Sugiyama Y, Inui A, Nagai T, Kusuhara H1. PubMed
  • Drug Metab Dispos. 2014;42:685-94. 6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. Imamura Y, Tsuruya Y, Damme K, Heer D, Kumagai Y, Maeda K, Murayama N, Okudaira N, Kurihara A, Izumi T, Sugiyama Y, Kusuhara H. PubMed
  • Drug Metab Pharmacokinet. 2014;29:266-71. Evaluation of the potency of telaprevir and its metabolites as inhibitors of renal organic cation transporters, a potential mechanism for the elevation of serum creatinine. Nakada T, Kito T, Inoue K, Masuda S, Inui K, Matsubara K, Moriyama Y, Hisanaga N, Adachi Y, Suzuki M, Yamada I, Kusuhara H. PubMed
  • Hepatology. 2014;59:1726-37. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, Tanaka Y, Kanai Y, Kusuhara H, Mizokami M, Wakita T. PubMed
  • Drug Metab Dispos. 2013;41:1859-66. Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17β-glucuronide, estrone-3-sulfate, and sulfobromophthalein. Izumi S, Nozaki Y, Komori T, Maeda K, Takenaka O, Kusano K, Yoshimura T, Kusuhara H, Sugiyama Y. PubMed
  • Pharm Res. 2014;31:136-47. Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. Kato K, Mori H, Kito T, Yokochi M, Ito S, Inoue K, Yonezawa A, Katsura T, Kumagai Y, Yuasa H, Moriyama Y, Inui K, Kusuhara H, Sugiyama Y. PubMed
  • Pharm Res. 2013;30:2880-90. Epigenetic regulation of organic anion transporting polypeptide 1B3 in cancer cell lines. Imai S, Kikuchi R, Tsuruya Y, Naoi S, Nishida S, Kusuhara H, Sugiyama Y. PubMed 
  •     Format: Abstract
  • J Pharm Sci. 2017;106:2558-2565. Possible role of Organic Cation Transporters in the distribution of [11C]Sulpiride, a dopamine D2 receptor antagonist. Takano H, Ito S, Zhang X, Ito H, Zhang MR, Suzuki H, Maeda K, Kusuhara H, Suhara T, Sugiyama Y. PubMed
  • Pharm Res. 2015;32:2538-47. Quantitative Evaluation of mMate1 Function Based on Minimally Invasive Measurement of Tissue Concentration Using PET with [(11)C]Metformin in Mouse. Shingaki T, Hume WE, Takashima T, Katayama Y, Okauchi T, Hayashinaka E, Wada Y, Cui Y, Kusuhara H, Sugiyama Y, Watanabe Y. PubMed
  • Org Biomol Chem. 2015;13:1113-21. The synthesis of [18F]pitavastatin as a tracer for hOATP using the Suzuki coupling. Yagi Y, Kimura H, Arimitsu K, Ono M, Maeda K, Kusuhara H, Kajimoto T, Sugiyama Y, Saji H. PubMed
  • Bioorg Med Chem. 2013;21:7584-90. The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo. Hume WE, Shingaki T, Takashima T, Hashizume Y, Okauchi T, Katayama Y, Hayashinaka E, Wada Y, Kusuhara H, Sugiyama Y, Watanabe Y. PubMed
  • J Pharmacol Exp Ther. 2013;347:193-202. Evaluation of Oatp and Mrp2 activities in hepatobiliary excretion using newly developed positron emission tomography tracer [11C]dehydropravastatin in rats. Shingaki T, Takashima T, Ijuin R, Zhang X, Onoue T, Katayama Y, Okauchi T, Hayashinaka E, Cui Y, Wada Y, Suzuki M, Maeda K, Kusuhara H, Sugiyama Y, Watanabe Y. PubMed
  • Clin Pharmacol Ther. 2013;94:33-6. Imaging in the study of membrane transporters. Kusuhara H. PubMed
  • Nucl Med Biol. 2013;40:643-50. Drugs interacting with organic anion transporter-1 affect uptake of Tc-99m-mercaptoacetyl-triglycine (MAG3) in the human kidney: therapeutic drug interaction in Tc-99m-MAG3 diagnosis of renal function and possible application of Tc-99m-MAG3 for drug development. Takahara N, Saga T, Inubushi M, Kusuhara H, Seki C, Ito S, Oyama N, Yokoyama O, Sugiyama Y, Fujibayashi Y. PubMed

PubMed

Tokyo, Japan

KUSUHARA HIROYUKI.jpg

Last update: October 2021